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Abstract The current evidence-based guideline on self-
medication in migraine and tension-type headache of the
German, Austrian and Swiss headache societies and the
German Society of Neurology is addressed to physicians
engaged in primary care as well as pharmacists and
patients. The guideline is especially concerned with the
description of the methodology used, the selection process
of the literature used and which evidence the recommen-
dations are based upon. The following recommendations
about self-medication in migraine attacks can be made: The
efﬁcacy of the ﬁxed-dose combination of acetaminophen,
acetylsalicylic acid and caffeine and the monotherapies with
ibuprofen or naratriptan or acetaminophen or phenazone are
scientiﬁcally proven and recommended as ﬁrst-line therapy.
None of the substances used in self-medication in migraine
prophylaxis can be seen as effective. Concerning the self-
medication in tension-type headache, the following therapies
can be recommended as ﬁrst-line therapy: the ﬁxed-dose
combination of acetaminophen, acetylsalicylic acid and
caffeine as well as the ﬁxed combination of acetaminophen
and caffeine as well as the monotherapies with ibuprofen
or acetylsalicylic acid or diclofenac. The four scientiﬁc
societies hope that this guideline will help to improve the
treatment of headaches which largely is initiated by the
patients themselves without any consultation with their
physicians.
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recommendations  Combined analgesics  Fixed-dose
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Prescription-free medication  Self-medication  Tension-
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Introduction
The ﬁrst ‘‘evidence-based guidelines on the self-medication
of migraine and tension-type headache’’ were presented by
the German Migraine and Headache Society (DMKG) in
2004 [1]. Although the guidelines from 2004 have been
widely disseminated and have attracted broad attention, it
remains important to emphasise the particular importance
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suggestions for the self-medication of headache are still
given based solely on individual experiences, on a subjec-
tively limited selection of studies, on misinterpretations, or
on results of methodologically unacceptable studies. New
treatment alternatives and new scientiﬁc ﬁndings from the
past few years have necessitated an updating of the guide-
lines of 2004. These were compiled together with the
German Society of Neurology (DGN), the Austrian Head-
ache Society (O ¨KSG) and the Swiss Headache Society
(SKG). Thus, the advice for patients regarding self-medi-
cation of migraine and tension-type headache is for the ﬁrst
time in the German-speaking countries evidence-based.
Headache types
About 90% of people with headaches suffer from either
migraine, tension-type headache or a combination of the
two. From a medical perspective these are not dangerous
even though they can, in part, encroach quite considerably
on the sufferer’s quality of life. While there is broad
knowledge about the pathophysiological mechanisms of
migraine with and without aura, the pathophysiology of
tension-type headache is largely unknown. According to
the current headache classiﬁcation of the International
Headache Society (IHS) [2], peripheral mechanisms are
very likely to play an important role in sporadic and in
frequently occurring episodic tension-type headache with
or without association of pericranial pain sensitivity
(ICHD-II: 2.1 and 2.2). In contrast, central pain mecha-
nisms are thought to be paramount in chronic tension-type
headache (ICHD-II: 2.3). Many patients are unaware of the
association between pain and tensions in the head and
shoulder muscles and their increased sensitivity to pain in
manual palpation, although this occurs in approximately
half of patients. This pain and tension of the pericranial
muscles is frequently perceived by patients as an illness in
its own right, and is thus additionally treated with anal-
gesics independent of their headache disease.
Self-treatment of primary headaches
Primary headaches such as migraine with and without aura
and episodic tension-type headache can be treated by the
patients him- or herself. However, the ﬁrst diagnosis should
be made by a physician and additional visits are recom-
mended when:
• headaches occur more than 10 days per month,
• headaches are accompanied by additional symptoms
such as motor weakness, sensory, visual or balance
disturbances, double vision or vertigo,
• headaches are accompanied by mental or cognitive
changes such as disturbances of short-term memory or
disturbances of orientation to time, place and person,
• headaches manifest for the ﬁrst time beyond age 40,
• headaches are unusual in intensity, duration and/or
localisation,
• headaches ﬁrst appear during or after physical exercise
and/or are very severe and radiate out from the neck,
• headaches are accompanied by high fever,
• headaches appear after head injury,
• headaches increase in frequency, intensity and duration
despite treatment,
• headaches occur together with epileptic seizures and
disturbances in consciousness,
• headaches no longer respond to the previously effective
medications.
In case of doubt, a visit to the doctor is always advisable.
Selection of the evaluated active ingredients and active
ingredient combinations
These recommendations for the self-medication of mig-
raine and tension-type headache should provide help for
the affected patients and physicians in selecting suitable
medicines for self-medication. Only pharmaceutical med-
ications and ﬁxed-dose combinations thereof, which are not
subject to a doctor’s prescription in Germany, Austria and
Switzerland, are evaluated. Based on standard units (tab-
lets, suppositories etc.), together, these represented at least
80% of the self-medication market in the three countries in
2007. In addition, for acute treatment, naratriptan is eval-
uated (available in Germany without prescription since
2007) and as prophylactics, cyclandelate, butterbur and
magnesium (not permitted as self-medication drugs in
Germany) are assessed. The individual and maximum daily
doses of the analgesics or ﬁxed-dose combinations, as well
as those of naratriptan, can differ in the three countries, and
not all active ingredients or combinations thereof are
available without prescription in all three countries.
Homeopathic medicines are not considered in these
recommendations, as they should be prescribed in the
framework of a multidimensional therapeutic concept.
Although dietary supplements do not constitute medicinal
products, a series of active ingredients and particularly
ﬁxed-dose combinations are offered as ‘‘dietetic foodstuff
for special medical purposes (balanced diet)’’, for instance
‘‘for the treatment of migraine’’. For this reason, a-lipoic
acid, the coenzyme Q10, riboﬂavin, orally administered
magnesium and melatonin which is subject to prescription
in Europe are included in the scientiﬁc evaluation of these
recommendations.
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These therapy recommendations correspond to the quality
features of an ‘‘evidence-based expert guideline’’ which is
characterised by the systematic research evaluation and
synthesis of the best available scientiﬁc evidence, and
quality assurance through the detailed explanation of the
methods used, the underlying goals, values, premises and
scientiﬁc evidence, which are all documented in a com-
prehensible and complete manner [3–8]. In the develop-
ment of these recommendations the necessary decisions of
the group of authors ensued in the framework of a priori
deﬁned codes of practice.
Literature search
Systematic literature searches with the goal of identifying
all clinical headache studies for the active ingredients or
active ingredient combinations of interest were conducted
using MEDLINE and the Cochrane Central Register of
Controlled Trials. The following search structure was
applied for the active ingredients already considered in the
therapy recommendations of 2004 for the period of January
2002 to December 2007, and for the newly added active
ingredients for the period 1966 to December 2007:
[(\drug[) and (headache# or migraine) and clinical
trial]
If the search did not result in any hits, the criterion
clinical trial was omitted.
These very simple search structures aimed above all to
minimise the ‘‘retrieval bias’’, i.e. the non-discovery of
published literature. As a systematic literature search is
also unable to offer any guarantee of discovering all rele-
vant publications [9], it was supplemented by a manual
literature search of the authors’ literature collections,
which led in particular to the identiﬁcation of non-English-
language publications [10], consequently reducing a pos-
sible ‘‘language bias’’.
Primarily, the search was limited to publications in
English and German. Corresponding MEDLINE or Coch-
rane literature searches were also conducted for the dietary
supplements a-lipoic acid, coenzyme Q10, riboﬂavin,
orally administered magnesium and melatonin (only
available on prescription). In this respect attention was paid
to the fact that not all relevant journals on dietary sup-
plements are recorded in MEDLINE [11].
Literature selection (search criteria)
To be included in these therapy recommendations, the
publications had to fulﬁl the following criteria regarding
study quality and scientiﬁc evidence:
• Full publication of double-blind controlled, clinical
studies on the treatment of headache disorders with
medications that can be obtained over-the-counter in
Germany, Austria or Switzerland, and which in terms of
individual dose, or where applicable daily dose, do not
exceedthemaximumdosesavailablewithoutprescription;
• controlled studies without placebo group were only
included in the evaluation if there was active control of
a drug or ﬁxed-dose combination thereof, whose
efﬁcacy is proven in terms of these recommendations.
To avoid bias [12, 13], publications which fulﬁlled one
or several of the following criteria were excluded:
• Abstracts, congress posters, congress information
• Observational studies
• Casuistics and clinical case series
• Clinical studies in which the clinical symptoms of
headache disorders only constitute an accompanying
criterion.
• Short publications
• Unpublished study reports
• Pharmacokinetic or bioavailability studies
• Review articles
• Clinical studies with children
‘‘Pharmacy-based observational studies’’ or ‘‘pharmacy-
based post marketing surveillance studies’’ are suitable for
gaining insights into the intended use and for the safety or
tolerability of medicines [14]. However, they are not suit-
able to prove the efﬁcacy of medicines as they do not fulﬁl
the underlying scientiﬁc criteria for this purpose [12, 15–
21], such as:
• Randomisation of individual patients (not of
pharmacies)
• Blinding
• Placebo control, which is particularly essential for
(headache) pain therapy due to the variable placebo
effect [22]
• Quality assurance (monitoring, source data veriﬁcation,
audits) are only possible in a pharmacy observational
study to a very limited extent, or not at all.
• Responder rate and analysis of ‘‘missing values’’
• The ‘‘branding’’ (trademark) as part of the placebo
effect
• Presence of a speciﬁc selection bias (‘‘users of a
particular preparation in the pharmacy observational
study’’ rate ‘‘their medicine’’).
In order to avoid a ‘‘multiple publication bias’’, i.e. a
distortion of the evaluation through a multiple publication
of results of the same study, only the qualitatively best
publication was evaluated in each case. Short publications
do not contain all of the necessary information for an
J Headache Pain (2011) 12:201–217 203
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congress posters, congress information and overview works
(reviews) [24].
Evaluation criteria
Evaluation criteria for the individual clinical studies
The therapy studies identiﬁed as ‘‘clinically relevant’’ for
the evaluation of drugs and ﬁxed-dose combinations
thereof were rated on the one hand in terms of ‘‘study
quality’’ (this comprises among other criteria the method-
ology, design, and internal and external validity), and on
the other hand in terms of the ‘‘scientiﬁc evidence’’, i.e. the
degree of proven effect (efﬁcacy).
Study quality: Study quality was rated on a 4-point scale
(fromAtoD)onthebasisofthemethodofEvansandPollock
[25] and of a specially developed study quality score
(Table 1), the evaluation categories of which had been a pri-
ori deﬁned. The method of Evans and Pollack constitutes a
score system with 33 items. The study quality score empha-
sises quality features which are of particular importance for
the development of these therapy recommendations.
Scientiﬁc evidence: The scientiﬁc evidence, which rates
the results of the study concerned for the respective ques-
tion, was categorised in accordance with the guidelines of
the US Headache Consortium [26, 27] by means of a ﬁve-
point scale (???; ??; ?;( ?); =).
Evaluation criteria for the active ingredients or ﬁxed-dose
combinations
We refrained from using a pool of data from the therapy
studies identiﬁed as ‘‘clinically relevant’’, as the small
amount of studies for each active ingredient or ﬁxed-dose
combination differ too greatly in methodological terms in
many cases.
Quality of scientiﬁc evidence: The quality of scientiﬁc
evidence was rated on a 4-point scale from A to D.
Scientiﬁc evidence of efﬁcacy: The scientiﬁc evidence of
efﬁcacy was rated on a 5-point scale, which had also been
a priori deﬁned, from ??? to 0. Due to large differences
in design, in the examined endpoints, and in the sample
sizes, we refrained from conducting a meta-analysis, as
was also the case in the recommendations of 2004 [28, 29].
Hence, no effect measures such as Odds Ratios or the like
are available.
Clinical impression of effectiveness: The clinical
impression of effectiveness was rated by the authors on a 5-
point scale in accordance with the guidelines of the US
Headache Consortium from ??? to 0 [26, 27].
Clinical impression of tolerability: The clinical
impression of tolerability was rated by the authors on a 5-
point scale in accordance with the guidelines of the US
Headache Consortium [26, 27] as well as further literature,
from ??? to 0.
Recommendations for medicinal therapy
On the basis of evaluations of the active ingredients or
combinations thereof regarding their quality, and the sci-
entiﬁc evidence of efﬁcacy, the recommendations for
medicinal therapy of migraine and tension-type headache
were updated under consideration of the clinical impres-
sion of effectiveness. As an identical methodology was
applied in the therapy recommendations of 2004 and the
current update, the evaluations of the therapy studies from
2004, supplemented with the evaluations of the newly
added studies, formed the basis for the following three
recommendation categories:
• ‘‘Remedy of ﬁrst choice’’: this recommendation was
only assigned if
(a) the quality of scientiﬁc evidence was rated with ‘‘A’’,
(b) the scientiﬁc evidence of efﬁcacy was rated with at
least ‘‘??’’,
(c) the clinical impression of effectiveness was rated with
at least ‘‘??’’, and
(d) the tolerability was rated with ‘‘??’’.
• ‘‘Remedy of second choice’’: this recommendation was
only given if
(a) the quality of scientiﬁc evidence was rated with ‘‘B’’,
(b) the scientiﬁc evidence of efﬁcacy was rated with at
least ‘‘(?)’’,
(c) the clinical impression of effectiveness was rated with
at least ‘‘?’’, and
Table 1 Study-quality score
1 Clear deﬁnition of the objective of the study
2 Study design adequate for the objective of the study
3 Clear deﬁnition of the primary endpoint
4 Clear deﬁnition of the secondary endpoints
5 Adequate blinding of the study (at least double-blind)
6 Adequate randomisation and adequate description of the
randomisation
7 Adequate presentation of early terminations/withdrawals from the
study
8 Placebo-control group
9 A priori sample size calculation
10 Patient population representative of self-medication (patients
e.g. with mild to moderately severe migraine and/or tension-type
headache; no in-patients)
11 Adequate statistical methods and analysis
12 Correct interpretation of the statistical results
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• ‘‘only in individual cases’’: This advice was issued if
(a) the quality of scientiﬁc evidence was rated with ‘‘C or
D’’,
(b) the scientiﬁc evidence of efﬁcacy was poorer than
‘‘(?)’’,
(c) the clinical impression of efﬁcacy was rated with at
least ‘‘?’’, and
(d) the tolerability was rated with at least ‘‘?’’.
The category ‘‘only in individual cases’’ is not a rec-
ommendation in the actual sense; rather, it aims to take into
account the circumstance that different drugs and ﬁxed-
dose combinations thereof are effective and tolerated based
on the clinical impression, but there is currently no or only
deﬁcient scientiﬁc evidence available on their efﬁcacy in
the treatment of migraine and tension-type headache.
Differentiated recommendations
within a recommendation category
With these therapy recommendations, the available com-
parative studies were used for the ﬁrst time to depict pos-
sible differences in efﬁcacy between the individual active
ingredients or ﬁxed-dose combinations within an evaluation
category. The basis for the consisted of therapeutic com-
parative studies which were rated with A or B regarding
quality of scientiﬁc evidence in the recommendations of
2004 or in the supplementary evaluations of this update.
Only those comparative studies were considered in which
active ingredients or active ingredient combinations were
compared with one another in doses, which are permitted
for self-medication in terms of these recommendations.
The evaluation categories were a priori deﬁned as
follows:
• ‘‘clearly superior’’ (): Results of at least one study,
evaluated as conﬁrmatory, show a statistically signif-
icant better efﬁcacy in favour of one of the treatments
in terms of the primary endpoint. Furthermore, a
consistency is also shown regarding superior efﬁcacy
in the secondary endpoints, and there are no contra-
dictory therapeutic comparative studies (quality of
scientiﬁc evidence: A or B).
• ‘‘superior’’ ([): Results of at least one study, evaluated
as conﬁrmatory, show a statistically signiﬁcant better
efﬁcacy in favour of one of the treatments in terms of
the primary endpoint. There are no contradictory
therapeutic comparative studies (quality of scientiﬁc
evidence: A or B).
• ‘‘not superior’’ ([[=\]): Results of one study, evaluated
as conﬁrmatory, do not show statistically better efﬁcacy
(test of superiority: ‘‘superiority trial’’) in the primary
endpoint in favour of one of the treatments. These
studies are not to be confused with the so-called
‘‘equivalence’’ or ‘‘non-inferiority’’ studies (see [13, 30,
31]).
• ‘‘no comparative studies’’ ([*]): indicated when no
comparative studies are available.
From the general evaluation of the comparative studies,
or if no such studies are available, the order of mentions of
the active ingredients or ﬁxed-dose combinations within a
recommendation category ensues from the evaluation of
the quality of scientiﬁc evidence, the scientiﬁc evidence of
efﬁcacy, the clinical impression of effectiveness and the
tolerability.
Results of the systematic literature search
For the total of 30 active ingredients or active ingredient
combinations, the systematic literature search taking into
account both formulations of the search terms (i.e. with and
without the term ‘‘clinical trial’’) resulted in 148 hits in
MEDLINE and 67 in Cochrane. Excluding multiple cita-
tions within the search, 139 hits remained in MEDLINE;
no multiple citations occurred in Cochrane. In accordance
with the inclusion and exclusion criteria of the search, and
considering the respective permitted dosage and applica-
tion form for each drug or each ﬁxed-dose combination, 37
relevant publications were identiﬁed in MEDLINE, and 22
relevant publications were found in Cochrane for the
search period of January 2002 to December 2007. For
ASA ? lithium, ASA ? sodium, ASA ? vitamin C ?
caffeine, diclofenac, dimenhydrinate, dimenhydrinate ?
paracetamol, lavandula ? peppermint, naratriptan, phe-
nazone ? propyphenazone and propyphenazone ? caf-
feine, the search was conducted for the period from 1966 to
2007, as due to their importance in at least one of the three
countries (A, CH and D), these active ingredients and
ﬁxed-dose combinations had been newly added to these
therapy recommendations. In accordance with the proce-
dure of recommendations of 2004 [1], therapy studies in
which both migraine and tension-type headache were
treated were considered in the evaluation of both headache
forms. It should be noted in this respect that in one study of
approximately 1,750 headache patients, only 60% of the
patients whose headache had been diagnosed on the basis
of anamnesis corresponded with the diagnosis of headache
episodes treated in the study [32]. This should also apply
for other headache studies with OTC analgesics.
For the following drugs or ﬁxed-dose combinations, as
in 2004 [1], no clinically relevant therapy studies are
available:
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naproxen sodium (in doses up to 220 mg),
propyphenazone
• for the combination analgesics: ASA ? caffeine,
ASA ? lithium, ASA ? sodium, ASA ? vitamin C,
ASA ? vitamin C ? caffeine, ASA ? paracetamol ?
vitamin C, paracetamol ? propyphenazone ? caffeine,
phenazone ? paracetamol ? caffeine, phenazone ?
propyphenazone
• for the phyto-combination: lavandula ? peppermint
• for migraine prophylactics: cyclandelate
In view of the frequent use of antipyretic analgesics and
other headache and migraine drugs for self-medication
worldwide, the number of adequate, randomised and con-
trolled clinical studies is low. Nevertheless, it can be
established that in the last few years, several studies cor-
responding to the ‘‘state of the art’’ have been published,
which now ﬁnd their way into the current recommenda-
tions. Including the additions from the manual searches, a
total of 35 studies, published in 34 publications [33–66] are
newly considered in these recommendations compared to
those from 2004 [1].
Recommendations for medicinal therapy
From the German Migraine and Headache Society
(DMKG), the German Society of Neurology (DGN), the
Austrian Headache Society (O ¨KSG) and the Swiss Head-
ache Society (SKG), the following of the mono-analgesics
and ﬁxed-dose combinations available for self-medication
of headaches in Germany, Austria and Switzerland are
recommended:
• For migraine: The ﬁxed-dose combination ASA ? par-
acetamol ? caffeine (as the highlighted recommenda-
tion); ASA, ibuprofen, naratriptan, paracetamol and
phenazone as further remedies of ﬁrst choice. None of
the migraine prophylactics received a recommendation.
• For tension-type headache: The ﬁxed-dose combination
ASA ? paracetamol ? caffeine (as the highlighted
recommendation); ASA, diﬂofenac (12.5 and 25 mg),
ibuprofen (only 400 mg) and the ﬁxed-dose combina-
tion paracetamol ? caffeine as further remedies of ﬁrst
choice, paracetamol as a remedy of second choice.
The detailed evaluations can be found in Tables 2, 3, 4.
Remarks on the analysed studies
The following points should be noted from the analysis of
the studies:
• The study quality of 13 studies, all published in the
period between 1997 and 2006, were evaluated with
‘‘A’’, while several ‘‘B’’ studies only narrowly missed
the ‘‘A’’ rating. The study quality has improved
compared to the recommendations of 2004 and the
publications corresponded more well to the require-
ments of the ‘‘CONSORT statement’’ [67]. Neverthe-
less, information gaps in the publication of clinical
studies still too frequently remained open, rendering it
difﬁcult to evaluate them [68].
• For many of the studies evaluated as ‘‘A’’ regarding the
study quality, in terms of the question of interest, the
difference in efﬁcacy compared to the placebo effect
was nevertheless not a priori deﬁned as a primary
endpoint. If it was only examined as a secondary
endpoint, the evaluation ‘‘no conﬁrmatory proof of
efﬁcacy for…’’ is made. In the case of several primary
endpoints, for an ‘‘A’’ rating, the problem of multiple
statistical testing had to be discussed or considered
accordingly in the statistical methodology.
Despite the overall improved study quality, again, var-
ious methodological weak points were notable in the ana-
lysed studies, including:
• Lack of a priori deﬁnition of the primary endpoint (to
be tested in a conﬁrmatory manner) and lack of an
unambiguous delimitation for the secondary endpoints
(to be analysed descriptively/exploratively).
• Consequently, multiple statistical testing of several
endpoints without or with only insufﬁcient adjustment
of the chosen signiﬁcance level, or the use of inade-
quate statistical methods [21, 69–71].
• Inadequate distinction between descriptive statistics
and inferential statistics. Descriptive statistics summa-
rise the study results and only apply for the patients in
the concrete study. Inferential statistics enable a
generalisation of the study results beyond the study
population [72]. In various publications (descriptive
statistically) signiﬁcant results of secondary endpoints
are repeatedly incorrectly drawn upon as proof of the
efﬁcacy of a treatment. These incorrect statements are
found particularly frequently in the abstracts, the
discussion and the conclusion of the respective publi-
cations. Consequently, they also clearly violate the
CONSORT guidelines [67] regarding interpretation of
the results under consideration of the study hypotheses,
the possible causes of distortions (‘‘bias’’) and the
problems brought about by multiple statistical testing
and multiple target criteria. This thus also impedes the
generalisablity of study results (external validity) [67].
• Lack of a priori deﬁned sample size calculations
leading to insufﬁcient sample sizes and ultimately
insufﬁcient statistical power [73]; studies with an
206 J Headache Pain (2011) 12:201–217
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123insufﬁcient sample size can thus lose their ethical
justiﬁcation [74].
• Insufﬁcient description of the research question, study
methodology, implementation and statistical analysis of
the study (e.g. lack of or insufﬁcient information on
blinding, on procedure and on ensuring randomisation,
on study dropouts, on conﬁdence intervals) [75].
The deﬁnition of the primary endpoints was not con-
sistent in the various studies. This renders the comparative
evaluation of the scientiﬁc evidence for the efﬁcacy of the
individual drugs and ﬁxed-dose combinations more difﬁ-
cult. For this reason, they were evaluated as described by
the study authors. Finally, therapeutic effect was usually
greater in the older studies than in the more recent ones.
This phenomenon which is often described in the literature
is attributed among other things to a ‘‘fading of reported
effectiveness’’, brought about in particular through baseline
differences [76] and to other systematic distortions.
Remarks on active ingredients and active ingredient
combinations
The following remarks on several of the analysed studies
should help to make the evaluations in these recommen-
dations transparent and comprehensible.
Acetylsalicylic acid (ASA)
In the so-called ‘‘EMSASI study’’ with a double-blind
randomised, three-way cross-over design, 312 patients with
migraine were each administered a single dose of 1,000 mg
ASA, 400 mg ibuprofen, 50 mg sumatriptan and placebo
[37]. The study documents the efﬁcacy of 1,000 mg ASA as
an effervescent tablet compared to placebo in the percent-
age responder rate of the 2-h value (4-point verbal scale).
As all other comparisons only constitute secondary end-
points, their results only count as descriptive for the study
population, cannot be generalised and can therefore not be
taken into account for the differentiated recommendations
within an evaluation category. For instance, in the study,
although the question is posed of whether 1,000 mg ASA is
just as effective as 50 mg sumatriptan or as 400 mg ibu-
profen, this is not reﬂected in the study design. To achieve
this, an equivalence approach with an a priori deﬁned non-
inferiority margin would have to have been chosen [30, 31,
77]. The study therefore shows neither an equivalence of
1,000 mg ASA with sumatriptan 50 mg, nor with ibuprofen
400 mg, and can equally not be seen as proof of efﬁcacy for
sumatriptan 50 mg or ibuprofen 400 mg. Unfortunately,
these results are wrongly interpreted and reported on
numerous occasions in this respect [78–81].
In a ﬁve-arm, double-blind randomised parallel group
study with the treatment groups ASA 500 and 1,000 mg,
paracetamol 500 and 1,000 mg and placebo, a total of 638
patients with episodic tension-type headache were included
in the intention-to-treat analysis 542 [63]. As a primary
endpoint, the comparison of 1,000 mg ASA compared to
placebo was established in the percentage responder rate of
the 2-h value (deﬁnition 4-point verbal rating scale so-
called Glaxo criterion). All other comparisons were
declared as secondary endpoints, ‘‘considered hypothesis-
generating in nature’’, and thus only to gain hypotheses for
further investigations. The superior efﬁcacy of 1,000 mg
ASA compared to placebo could be proved in this study.
As all other comparisons merely constitute secondary
endpoints and cannot be generalised, they can also not be
taken into account for the differentiated recommendations
within an evaluation category. The selected manner of
presenting the results in this publication renders it con-
siderably more difﬁcult to interpret them correctly. This
could be a reason why this study has been misinterpreted
on several occasions [78, 82].
Acetylsalicylic acid ? paracetamol ? caffeine
In a large, randomised, double-blind study with a parallel
group design, only patients were included who had suc-
cessfully treated their headaches themselves with pre-
scription-free pain medications [39]. The approximately
1,750 patients therefore represented typical OTC headache
patients. In the primary target criterion, ‘‘time until
reaching a 50% pain reduction’’, the superior efﬁcacy of
two tablets of the ﬁxed-dose combination of ASA ? par-
acetamol ? caffeine was shown compared to 1,000 mg
ASA, 1,000 mg paracetamol, the combination of ASA and
paracetamol, and compared to 100 mg caffeine and pla-
cebo. All verum treatments differed signiﬁcantly from
placebo (with the exception of caffeine). The statistical
analyses of the secondary endpoints also conﬁrmed the
Table 4 Recommendations of the DMKG, DGN, O ¨KG and SKG for self-medication with migraine-prophylactics
Drug Quality of scientiﬁc
evidence
Scientiﬁc evidence
of efﬁcacy
Clinical impression
of effectiveness
Clinical impression
of tolerability
Commentary Recommendation
for self-medication
Cyclandelat D 0 ?? ? Only in individual cases
Petasites C ?? ? ? ? Only in individual cases
208 J Headache Pain (2011) 12:201–217
123superiority of the triple combination compared to the
combination without caffeine, as well as all single sub-
stances and placebo, meaning that the results are consis-
tent. Their clinical relevance was conﬁrmed through
analyses of the global efﬁcacy rating of the patients [83].
Diclofenac–potassium
As both 12.5 and 25 mg diclofenac–potassium were swit-
ched from the ‘‘prescription only’’ status to selfmedication
in Germany in the last few years, they are considered for
the ﬁrst time in these recommendations. In a double-blind
randomised, multicentre study, diclofenac–potassium 12.5
and 25 mg, 400 mg ibuprofen and placebo were compared
in 684 patients with episodic tension-type headache in a
parallel group design [49]. As a ‘‘primary efﬁcacy vari-
able’’, the TOTPAR-3, the weighted ‘‘total pain relief’’,
was indicated over a period of 3 h following intake of the
medication. This indication is insufﬁcient as a deﬁnition of
an endpoint, as only the measurement parameter, but not
the allocation of the treatment group comparisons can be
given as a ‘‘primary’’ or ‘‘secondary’’ endpoint. The for-
mulation of the null hypothesis is also lacking. If it can be
assumed that the study should primarily yield the proof of
efﬁcacy for diclofenac 12.5 and 25 mg, and all other
comparisons were deﬁned as secondary endpoints, then the
indicated statistical procedure of ‘‘Fisher’s protected pro-
cedure’’ would be sufﬁcient for the multiple conﬁrmatory
comparisons of diclofenac–potassium 12.5 and 25 mg
versus placebo. If all three groups were to be tested in a
conﬁrmatory manner, then it would be necessary to carry
out Fisher’s protected procedure ‘‘within each group’’ on
the a/3 signiﬁcance level. From the overall picture of the
publication, it can be concluded that the comparisons of
‘‘ibuprofen 400 mg versus placebo’’, ‘‘diclofenac–potas-
sium 12.5 mg versus placebo’’ and ‘‘diclofenac–potassium
25 mg versus placebo’’ should constitute the primary
endpoints of the study and the comparisons between the
verum treatments the secondary endpoints. With this study
which can otherwise be attested as having a good study
quality, the proof of efﬁcacy for 12.5 and 25 mg diclofe-
nac–potassium is yielded for the acute treatment of tension-
type episodic headache. The assertion that ‘‘Moreover, this
efﬁcacy is similar to that of ibuprofen 400 mg …’’ is only
descriptively valid for the study population and cannot be
generalised; for this reason, the study was also not taken
into account for the differentiated recommendations within
an evaluation category.
Naratriptan
Naratriptan became available as a single dose of 2.5 mg
without prescription in Germany in 2006. In total, the
systematic literature searches resulted in seven clinically
relevant therapy studies. Five of these studies, however,
cannot be evaluated as conﬁrmatory evidence for 2.5 mg
naratriptan for the treatment of migraine as they were
either dose-ﬁnding studies [47, 48] or the primary end-
points referred to other research questions or were not
clearly deﬁned [34, 40, 55].
In a double-blind randomised, multi-centre study,
naratriptan was compared in the doses 2.5 or 1 mg versus
placebo, 2.5 versus 0.25 mg or 0.1 mg and 1 versus 0.1 mg
in 613 patients in a parallel group design [48]. Again, only
the measurement parameter, and not the deﬁnition of the
treatment group comparisons, is given as ‘‘primary’’ or
‘‘secondary’’ endpoint. Multiple statistical testing is not
considered in the design of the study either in the form of a
hierarchical test procedure or in the form of a a-adjustment.
The results compared to placebo can only be judged as
descriptive and thus can not be generalised and do not
constitute a conﬁrmatory proof of efﬁcacy.
In a further dose-ﬁnding study using a parallel group
design, a single dose of 1, 2.5, 5, 7.5 and 10 mg naratriptan
as well as 100 mg sumatriptan and placebo were compared
in 643 migraine patients [47]. As multiple statistical testing
is not considered in the design of the study, comparisons
versus placebo can only be judged as descriptive and do not
constitute a conﬁrmatory proof of efﬁcacy.
With a single dose of rizatriptan (10 mg), naratriptan
(2.5 mg) and placebo, 522 migraine patients were treated
in a randomised, double-blind parallel group study (double-
dummy) [34]. The test hypothesis ‘‘rizatriptan 10 mg
would be superior to naratriptan 2.5 mg in time to head-
ache relief up to 2 h after drug administration’’ is formu-
lated in a methodologically exemplary manner, and the
question of multiple statistical testing is correctly addres-
sed: ‘‘as there was only one primary endpoint and one
primary comparison, there was no need for multiplicity
adjustment for primary time point’’. The comparisons
versus placebo are consequently secondary endpoints,
meaning that the study cannot be seen as a conﬁrmatory
proof of efﬁcacy for naratriptan in terms of these
recommendations.
In a randomised, double-blind parallel group study
comparable in terms of design, single doses of eletriptan
(40 mg), naratriptan (2.5 mg) and placebo were compared
in 548 migraine patients [40]. Again, the primary endpoint
is formulated clearly: ‘‘the primary comparison was
between eletriptan 40 mg and naratriptan 2.5 mg, and
consisted of the proportion of subjects with a headache
response at 2 h after the ﬁrst dose of study treatment for the
migraine attack’’. Moreover, the question of multiple sta-
tistical testing is correctly addressed: ‘‘no adjustment was
made for multiple comparisons’’. The comparisons versus
placebo are consequently secondary endpoints, meaning
J Headache Pain (2011) 12:201–217 209
123that the study can also not be seen as a conﬁrmatory proof
of efﬁcacy for naratriptan in accordance with these
recommendations.
Almost 700 migraine patients were treated in a ran-
domised, double-blind four-period cross-over study with a
single dose of 0.25, 1, and 2.5 mg naratriptan as well as
placebo [55]; however, the study was evaluated regarding
efﬁcacy as a parallel group comparison (sample size esti-
mation: 125 per group). Again, in this study, only the
measurement parameter is indicated, and no clear deﬁni-
tion is made of the treatment group comparisons as ‘‘pri-
mary’’ or ‘‘secondary’’ endpoint. In the study design,
multiple statistical testing is not considered either in the
form of a hierarchical test procedure or in the form of a a-
adjustment; thus it does not constitute a conﬁrmatory proof
of efﬁcacy for naratriptan 2.5 mg in line with these
recommendations.
Migraine patients (N = 347) who responded poorly to
sumatriptan were all treated in a two-phase study ﬁrst with
50 mg sumatriptan. Non-responders (N = 206) to suma-
triptan then received, in a randomised, double-blind par-
allel group design 2.5 mg naratriptan or placebo [61]. In
the primary endpoint ‘‘conversion from moderate or severe
pain to mild or no pain at 4 h after use of test medication’’,
naratriptan 2.5 mg proved to be statistically signiﬁcantly
superior to placebo treatment. However, the proof of efﬁ-
cacy was generated in a speciﬁc subgroup, namely
migraine patients who responded poorly to sumatriptan,
and therefore cannot be concluded for the general popu-
lation without further investigation.
Patients (N = 227) with menstrual migraine received, in
a randomised, double-blind parallel, group study, a single
dose of 2.5 mg naratriptan or placebo [54]. In the primary
endpoint, the ‘‘percentage of subjects who were completely
free of pain 4 h after medication’’, the naratriptan 2.5 mg
treatment proved to be statistically signiﬁcantly superior to
placebo treatment. Again, the proof of efﬁcacy refers to a
speciﬁc subgroup, namely female patients with menstrual
migraine, and cannot be concluded for the general popu-
lation without further investigation.
According to the general evaluation of naratriptan
2.5 mg, despite the various limitations in the available
studies,aproofofeffectivenessforthetreatmentofmigraine
can be assumed. As naratriptan and other triptans have not
yet been examined in typical self-medication patients, such
studies are necessary and desirable in the future [84].
Summary of efﬁcacy data
Table 5 provides a summary of efﬁcacy data of 11 ran-
domized clinical studies which are considered in the
evaluation of the recommendations for self-medication of
acute migraine attacks with and without aura or tension-
type headache, including only trials with drugs recom-
mended as ﬁrst or second choice.
Butterbur as a migraine prophylaxis
For a double-blind randomised, placebo-controlled, parallel
group study on migraine prophylaxis [85] including 60
migraine patients, who following a 4-week ‘‘run-in phase’’
had received either 50 mg Petasites hybridus extract for
12 weeks or placebo, a post-hoc reanalysis [36] was con-
ducted. The ‘‘frequency of migraine attacks per 4 weeks’’
was deﬁned as the primary efﬁcacy variable. In the anal-
ysis, the frequency of attacks was then determined con-
secutively for the verum and the placebo group over the 4-
month duration of the study. As neither a hierarchical test
procedure nor an adjustment of the signiﬁcance level for
multiple statistical testing ensued on the basis of the pri-
mary publication [85], this study can only be judged in
exploratory terms as a pilot study and cannot be evaluated
as a conﬁrmatory study in the sense of a proof of efﬁcacy.
In a double-blind randomised, placebo-controlled par-
allel group study (migraine prophylaxis), following a 4-
week run-in phase, 233 patients received 50 or 75 mg of a
Petasites hybridus extract or placebo [51]. In total, three
primary comparisons between the treatment groups were
deﬁned and tested, namely (1) 75 mg Petasites extract
versus placebo, (2) 50 mg Petasites extract versus placebo
and (3) 75 versus 50 mg Petasites extract. The multiple test
procedure was not taken into account either in the study
methodology or the results section of the publication, and
the chosen statistical procedure enables no conﬁrmatory
proof of efﬁcacy for any of the three endpoints.
Remarks on comparative studies
In the development of differentiated recommendations
within an evaluation category, it was only possible to
consider studies in which the comparison between the
drugs or ﬁxed-dose combinations constituted the primary
endpoint and which were rated with A or B regarding study
quality. In total, four studies met these criteria [39, 44, 56,
86]; three further studies could not be considered [37, 49,
63]. Further comparative studies on the determination of
the therapeutic status of the various active ingredients
would be necessary and desirable.
Remarks on the tolerability of the active ingredients
or active ingredient combinations
There continue to be few meaningful comparative studies
on the tolerability of prescription-free analgesics in their
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123Table 5 Summary of efﬁcacy data of 11 randomized clinical studies (only drugs recommended as ﬁrst or second choice)
Indication and drug Active drug Placebo Therapeutic
gain
Primary endpoint
of the study
Literature
reference
Migraine/ETTH
ﬁxed-dose combination of
500 mg ASA ? 400 mg
paracetamol ? 100 mg
caffeine
Secondary endpoints:
PID at 2 h VAS: 44.7 mm
C50% pain reduction at 2 h:
77% of patients
PID at 2 h VAS: 24.6 mm
C50% pain reduction at 2 h:
47% of patients
D = 20.1 mm
D = 30%
Kaplan–Meier estimator of the
proportion of patients with 50%
pain relief during the ﬁrst 4 h
after drug intake
Diener et al.
[39, 109]
Migraine
ﬁxed-dose combination of
500 mg ASA ? 500 mg
paracetamol ? 130 mg
caffeine
Primary endpoint:
TOTPAR-2 at 2 h: 2.7 TOTPAR-2 at 2 h: 2.0 D = 0.7
TOTPAR-2 sum of pain relief
scores at 2 h postdose
(5-point VRS)
Goldstein et al.
[44]
ETTH
ﬁxed-dose combination of
1,000 mg
paracetamol ? 130 mg
caffeine
Primary endpoint:
study 1: TOTPAR-4:
10.45 ± 0.20
study 2: TOTPAR-4:
10.54 ± 0.19
study 1: TOTPAR-4:
8.82 ± 0.30
study 2: TOTPAR-4:
7.86 ± 0.32
D = 1.63
D = 2.68
TOTPAR-4 sum of pain relief
scores at 4 h postdose
(5-point VRS)
Migliardi et al.
[56]
Migraine
1,000 mg ASA
Primary endpoint:
response rate at 2 h:
52.5% of patients
response rate at 2 h:
30.6% of patients D = 21.9%
Number of patients (in %) with
headache relief from grade
3 or 2 to grade 1 or 0 at 2 h
(4-point VRS)
Diener et al.
[37]
Migraine
1,000 mg ASA
Primary endpoint:
response rate at 2 h:
52% of patients
response rate at 2 h:
34% of patients D = 18%
Number of patients (in %) with
headache relief from grade
3 or 2 to grade 1 or 0 at 2 h
(4-point VRS)
Lipton et al.
[52]
ETTH
1,000 mg ASA
Primary endpoint:
response rate at 2 h:
(7-point VRS): 75.7%
response rate at 2 h:
(7-point VRS): 54.5% D = 21.2%
Number of patients (in %) with
headache relief to grade
1 or 0 at 2 h (7-point VRS)
Steiner et al.
[63]
ETTH
12.5 mg diclofenac-K
Primary endpoint:
TOTPAR-3: 5.23 ± 2.71
secondary endpoint:
complete pain relief at 2 h:
18.1% of patients
TOTPAR-3: 3.49 ± 3.02
complete pain relief at 2 h:
7.8% of patients
D = 1.74
D = 10.3%
TOTPAR-3 (time-weighted
sum of pain relief scores
at 3 h)
Kubitzek et al.
[49]
ETTH
25 mg diclofenac-K
Primary endpoint:
TOTPAR-3: 5.55 ± 2.95
secondary endpoint:
complete pain relief at 2 h:
22.6% of patients
TOTPAR-3: 3.49 ± 3.02
complete pain relief at 2 h:
7.8% of patients
D = 2.06
D = 14.8%
TOTPAR-3 (time-weighted
sum of pain relief scores
at 3 h)
Kubitzek et al.
[49]
ETTH
400 mg ibuprofen
Primary endpoint:
TOTPAR-3: 5.37 ± 3.07
secondary endpoint:
complete pain relief at 2 h:
21.9% of patients
TOTPAR-3: 3.49 ± 3.02
complete pain relief at 2 h:
7.8% of patients
D = 1.88
D = 14.1%
TOTPAR-3 (time-weighted
sum of pain relief scores
at 3 h)
Kubitzek et al.
[49]
Migraine
400 mg ibuprofen
Primary endpoint:
response rate at 2 h:
72.3% of patients
secondary endpoints:
PID at 2 h VAS: 1.23 ± 0.97
pain free (cumulative):
27.7% of patients
response rate at 2 h:
50% of patients
PID at 2 h VAS: 0.71 ± 0.87
pain free (cumulative):
13.4% of patients
D = 22.3%
D = 0.52
D = 14.3%
Number of patients (in %) with
headache relief from grade
3 or 2 to grade 1 or 0 at 2 h
(4-point VRS)
Kellstein et al.
[110]
Migraine
1,000 mg paracetamol
Primary endpoint:
response rate at 2 h:
57.8% of patients
secondary endpoint:
pain free (cumulative):
22.4% of patients
response rate at 2 h:
38.7% of patients
secondary endpoint:
pain free (cumulative):
11.3% of patients
D = 19.1%
D = 11.1%
Number of patients (in %) with
headache relief from grade
3 or 2 to grade 1 or 0 at 4 h
(4-point VRS)
Lipton et al.
[111]
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123recommended application, although such studies should be
encouraged [80, 87]. The controlled studies on the proof of
efﬁcacy are frequently ill-suited for generating reliable data
beyond acute use as for example the sample sizes are too
low in this respect. Safety and tolerability studies normally
include several thousand or ten thousand patients,
depending on the research question [88].
To date, only one study has compared the tolerability of
ASA, ibuprofen and paracetamol in short-term use (up to
7 days) [89]. Paracetamol and ibuprofen showed a com-
parable safety and tolerability, which was signiﬁcantly
superior to that of ASA. Further interesting approaches for
a comparative evaluation of the safety and tolerability of
non-narcotic analgesics [90] and triptans [91], respectively,
should be referred to at this point.
Evaluation of dietary supplements
For advising headache patients, it must apply in particular
also for the risk–beneﬁt evaluation of dietary supplements
that: ‘‘Academicians must resist pressure to present
unproven therapies as realistic alternatives for medications
with scientiﬁc proof of safety and efﬁcacy. They must
stress the value of evidence-based medicine and urge stu-
dents and pharmacists to recommend only those medica-
tions with evidence-based proof of safety and efﬁcacy’’
[77].
A notable number of studies with dietary supplements
have been conducted compared to medicine-based studies,
each with a very small number of subjects. For these
studies, the limitations formulated by McQuay and Moore
apply as follows: ‘‘The lessons are that information from
individual trials of small size should be treated with cir-
cumspection in pain and probably other therapeutic areas,
and that variations seen in trials of small size is probably
artefactual…’’ [92] or ‘‘A small trial has only a small
chance of correctly detecting a difference (or no difference)
at conventional levels of signiﬁcance’’, as West cautions in
his Editorial [93].
Magnesium
From the analyses of the therapy recommendations of
2004, it emerged that there was no proof of efﬁcacy in the
form of double-blind randomised studies for orally
administered magnesium in migraine prophylaxis. For this
reason, the evaluation ‘‘only in individual cases’’ was
given. As magnesium is not approved in Germany for
migraine prophylaxis, it is only listed in the text in these
recommendations, as with the other dietary supplements
and is no longer listed in the recommendation table.
As in 2004, the systematic literature search on magne-
sium in migraine prophylaxis resulted in four publications.
From a small, randomised, double-blind study in 24
patients with menstrual migraine [94], no statements on the
efﬁcacy of magnesium in migraine prophylaxis can be
derived. A further double-blind randomised study [95]i n
81 patients showed, after 3-month use, a statistically sig-
niﬁcant superiority of 600 mg magnesium compared to
placebo in the third treatment month. A double-blind ran-
domised study [96] which was to include 150 patients, was
abandoned following an interim evaluation of 69 patients,
as the superiority over placebo treatment, also of a 3-month
treatment with 486 mg magnesium, no longer appeared to
be achievable. This study is problematic with regard to
Table 5 continued
Indication and drug Active drug Placebo Therapeutic
gain
Primary endpoint
of the study
Literature
reference
ETTH
1,000 mg paracetamol
Secondary endpoint:
response rate at 2 h
(7-point VRS): 71.2%
response rate at 2 h
(7-point VRS): 54.5% D = 16.7%
Number of patients (in %) with
headache relief to grade
1 or 0 at 2 h (7-point VRS)
Steiner et al. [63]
Migraine
1,000 mg phenazone
Primary endpoint:
response rate at 2 h:
48.6% of patients
secondary endpoint:
pain free at 2 h postdose:
27.6% of patients
response rate at 2 h:
27.2% of patients
secondary endpoint:
pain free at 2 h postdose:
13.6% of patients
D = 21.4%
D = 14%
Number of patients (in %) with
headache relief from grade
3 or 2 to grade 1 or 0 at 4 h
(4-point VRS)
Go ¨bel et al. [42]
Migraine
2.5 mg nartriptan
Primary endpoint:
response rate at 4 h:
41% of patients
secondary endpoint:
response rate at 2 h:
25% of patients
response rate at 4 h:
19% of patients
response rate at 2 h:
10% of patients
D = 22%
D = 15%
Number of patients (in %) with
headache relief from grade 3 or
2 to grade 1 or 0 at 4 h
(4-point VRS)
Stark et al. [61]
ASA acetylsalicylic acid, ETTH episodic tension-type headache, PID pain intensity differences, therapeutic gain: deﬁned as response of the active drug minus placebo
response, TOTPAR total pain relief, VAS visual analog scale (100 mm), VRS verbal rating scale
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123various methodological points, meaning that it is not pos-
sible to correctly interpret the results of its primary end-
point. A further study [65] implemented in children cannot
be taken into account for these recommendations which are
targeted at adults. All studies were implemented with dif-
ferent magnesium salts and different galenic formulations
and doses, rendering the evaluation of the therapeutic
beneﬁt difﬁcult.
From an overall view of the available data, it is possible
to speak of substantiated evidence, but not of a proof of
efﬁcacy of magnesium for migraine prophylaxis. Further
randomised, placebo-controlled, double-blind studies
would be necessary for this purpose. Nevertheless, from a
purely clinical-pragmatic perspective, magnesium is fre-
quently used for migraine prophylaxis in pregnant women.
Coenzyme Q10
The systematic literature search on the coenzyme Q10
resulted in three publications on migraine prophylaxis, one
of which was a larger cases series on coenzyme Q10 sup-
plementation in children and adolescents [97] and one of
which was a small, open study in 32 migraine patients [98].
Frombothinvestigations,noproofofefﬁcacycanbederived
for the coenzyme Q10 for migraine prophylaxis due to
methodological reasons. A further small, double-blind ran-
domised study [99] in 43 patients did show a statistically
signiﬁcant superiority over placebo following 3-month use,
but this can be attributed to the surprisingly low placebo
effect. Methodological ambiguities clearly limit the
expressiveness of the study, such that from the overall view
oftheavailabledata,aproofofefﬁcacyofthecoenzymeQ10
for migraine prophylaxis cannot yet be judged as having
been provided. For this purpose, further randomised, pla-
cebo-controlled, double-blind studies would be necessary.
Riboﬂavin (Vitamin B2)
The systematic literature search for riboﬂavin and migraine
prophylaxis resulted in four publications. In one publica-
tion [100], a combination preparation was examined, but
contained no data on riboﬂavin as a single substance. From
two small, open, non-controlled studies in 23 [101] and 49
patients [102], no conclusions can be derived on the efﬁ-
cacy of riboﬂavin in migraine prophylaxis. In a further
small, double-blind randomised study [103] in 55 patients,
a statistically signiﬁcant superiority over placebo was
shown after 3-month use, but this can be attributed to the
surprisingly low placebo effect. From an overall view of
the available data, there are indications but no proof of the
efﬁcacy of riboﬂavin (vitamin B2) for migraine prophy-
laxis. For this purpose, a further, larger, randomised, pla-
cebo-controlled double-blind study would be necessary.
a-Lipoic acid
Whether the intake of a-lipoic acid is effective for migraine
prophylaxis was examined in a small study with 44 patients
[104]. This was methodologically insufﬁcient and did not
generate any statistically signiﬁcant results. The efﬁcacy of
a-lipoic acid can thus currently not be answered. Further
clinical studies would be necessary here.
Omega-3 fatty acids
The extent to which the intake of omega-3 fatty acids is
effective for migraine prophylaxis was examined in a lar-
ger, double-blind randomised, placebo-controlled parallel
group study [105]. Following 3-month use, no statistically
signiﬁcant superiority over placebo was shown for poly-
unsaturated omega-3 fatty acids in terms of attack fre-
quency in the third treatment month (primary target
criterion); thus, there was no proof of efﬁcacy.
Melatonin
Melatonin is a prescription medicine and not permitted for
migraine prophylaxis. Although the MEDLINE search
produced 87 hits for melatonin, no single randomised,
controlled clinical study was among them. The question of
whether the administration of melatonin is effective for
migraine prophylaxis cannot be answered on the basis of a
short publication on a small, open, uncontrolled study of 30
patients [106]. Further clinical studies would be necessary
for this purpose which the authors also call for in the cited
study [107, 108].
Combination of dietary supplements
According to the results of a systematic literature search,
no scientiﬁcally reliable proof of efﬁcacy for prophylaxis
or acute therapy of migraine has yet been generated either
for the individual dietary supplements or for combinations
of these supplements among one another and/or, for
example, with vitamins and trace elements. Thus, this
question remains unanswered.
Medication-overuse headache
Medication-overuse headache is a serious problem con-
cerning the therapy of some headache patients. On the
basis of the available literature results the four scientiﬁc
societies claim that patients who take headache- and
migraine medications on a regular basis on more than
10–15 days per month have an increased risk for the
development of medication-overuse headache independent
J Headache Pain (2011) 12:201–217 213
123of whether mono- or combined drugs are involved. More
important than the composition of the drugs is the fre-
quency of their consumption. The recommendation there-
fore states that headache- and migraine medications should
not be taken for more than three consecutive days and on
more than 10 days per month. However, the quality of
evidence for this recommendation based on consensus is
low. It is not clear how many patients are helped versus
how many are hurt (by pain under-treatment) by this
advice, as this has not been studied, as Scher et al. recently
stated [112]. All relevant aspects of this topic are going to
be discussed in a new treatment guideline for medication-
overuse headache, which is prepared by the DMKG, DGN,
O ¨KG and SKG within the next months.
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